Centene Corp(NYSE:CNC) will see widening margins as it expands into the fast-growing market for those patients receiving government health benefits who require particularly complex care, an analyst said Monday.
Last week, the St. Louis-based managed care company that specializes in Medicare and other government programs boosted its 2015 earnings forecast about 4 percent to between $2.70 and $2.82 a share.
Analysts on average expect $2.72 a share, according to Thomson Financial Network.
Cantor Fitzgerald’s Joseph France boosted his target on Centene more than 6 percent Monday to $85, maintaining a Buy rating.
France said the company is increasingly pushing into sectors requiring more complex care, counting the government’s Aged, Blind or Disabled Program, long-term care and patients eligible for multiple government-backed healthcare programs.
Centene Corp(NYSE:CNC) started its trading session with the price of $ 78.84 and closed at $ 79.07 by scoring + 0.74% and traded with total volume of 1.19M shares, while the average trading remained 1.36M shares. During last trade its minimum price was $ 78.51 and it gained the highest price of $ 79.94. Its market capitalization was $ 9.33B.
Alkermes Plc(NASDAQ:ALKS) declared that data from studies of the company’s pipeline of central nervous system (CNS) drug candidates in schizophrenia and depression, counting ALKS 3831, aripiprazole lauroxil and ALKS 5461, will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Fla., June 22-25, 2015.
Alkermes Plc(NASDAQ:ALKS) showing jumped of 0.03 % and closed at $63.93, after gaining total volume of 1.18M shares. Its opening price was $64.49. Its earnings per share(EPS) is $-0.25 and its beta value stands at 0.99 points and has total market capitalization of $9.50B and a total of 148.48M outstanding shares.
Valeant Pharmaceuticals Intl Inc(NYSE:VRX) declared that it has sold 4.2 million shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX; TSX: VRX) in brokers’ dealings on the NYSE. ValueAct Capital’s CEO Jeffrey W. Ubben said: “Mike Pearson and the Valeant team’s exceptional performance have once again cause our investment in Valeant to grow in value to well above 20% of our funds’ assets, and we are again compelled to reduce our position to rebalance our overall portfolio.
Valeant Pharmaceuticals Intl Inc(NYSE:VRX) reported the surge of 1.63% and closed at $ 233.95 , with the total traded volume of 1.17M shares and opening price was $ 230.61 . During last trade its minimum price was $ 230.23 and it gained its highest price of $ 234.81 and has a total of 341.19M outstanding shares and its total market capitalization is $ 78.21B.
Catalyst Pharmaceuticals Inc(NASDAQ:CPRX) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, stated financial results for the first quarter ended March 31, 2015.
2015 Business Achievements to Date:
- Confirmatory pre-NDA meeting with FDA regarding Firdapse(R) for LEMS
- Raised $34.9 million, net of expenses, in a public offering of shares of common stock
- Orphan Drug Designation of Firdapse(R) for treatment of Congenital Myasthenic Syndromes
- Richard J. Daly and Donald A. Denkhaus designated to Board of Directors
- Development and advancement of comprehensive commercialization and pre-launch plan
- Enrollment in expanded access program which allows LEMS and CMS patients early access to Firdapse(R)
- Recently presented Phase 3 trial results at the annual meeting of the American Academy of Neurology (AAN) in Washington, D.C.
Catalyst Pharmaceuticals Inc(NASDAQ:CPRX) reported the surge of 3.56 %, after closing price for the day was $4.07 and opening at the price of $3.94. Its total trading volume for the day was 1.16M shares, versus its average volume of 552,838.00 shares. Its earnings per share are $-0.24.